The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
The Possible Application of Ketamine in the Treatment of Depression in Alzheimer’s Disease
Open accessAbstract
Depression is a leading cause of disability globally, with a prevalence of 3.8% among the whole population, 5% of the adult population, and 5.7% of the elderly population over 60 years of age. There is evidence that depression is linked to certain neurodegenerative diseases, one being Alzheimer’s disease (AD). The efficacy of conventional antidepressants to treat depression in AD is conflicting, especially regarding selective serotonin reuptake inhibitors (SSRIs). A recent systemic review and meta-analysis of 25 randomized controlled trials including fourteen antidepressant medications showed no high efficacy in treating AD patients’ symptoms. However, ketamine, a nonselective N-methyl-D-aspartate (NMDA) receptor antagonist, can mediate a wide range of pharmacological effects, including neuroprotection, anti-inflammatory and anticancer properties, multimodal analgesia, and treatment of depression, suicidal attempts, and status epilepticus. Esketamine, which is ketamine formulated as a nasal spray, was approved by the Federal Drug Administration (FDA) in March 2019 as an adjuvant drug to treat treatment-resistant depression. NMDA receptor antagonists treat AD through offsetting AD-related pathological stimulation of subtypes of glutamate receptors in the central nervous system. Recent clinical findings suggest that ketamine may provide neuroprotection and reduce neuropsychiatric symptoms associated with AD. In the present investigation, we evaluate the potential role of ketamine and its postulated mechanism in AD management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“recent clinical findings suggest that ketamine may provide neuroprotection and alleviate neuropsychiatric symptoms associated with Alzheimer’s disease, due to its ability to act as an NMDA receptor antagonist and modulate brain inflammation and glutamate-related neurotoxicity [93].”
From Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review (2024) · cites this paper as [93]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · cited 1×
“Memory impairment, defined as the specific loss of the memory of a recent event, is an initial and most common symptom [17].”
BackgroundAntidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 1×
“Moreover, ketamine has a rapid and prolonged antidepressant effect compared to currently approved antidepressants [9,10].”
BackgroundComprehensive Review on Alzheimer’s Disease: Causes and Treatment
Breijyeh, Z., & Karaman, R. (2020) · Molecules · doi:10.3390/molecules25245789 · Cited by 2,789 · cited 1×
“Other estimates suggest that the number is around 50 million worldwide and is projected to reach 152 million by 2050 [14].”
BackgroundNMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609 · cited 1×
“The NMDA receptor inhibition independent mechanisms belong to the ketamine metabolites; (S)-norketamine and (2R,6R)-hydroxynorketamine (HNK) [35].”
BackgroundOwnby, R. L., Crocco, E., Acevedo, A., John, V., & Loewenstein, D. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.5.530 · Cited by 1,493 · cited 2×
“Study 2: [3] Adults 21–80 years of age with major depressive disorder (MDD) with a poor response to at least three therapeutic trials of an antidepressant.”
BackgroundMechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127 · cited 2×
“The efficacy of ketamine may be attributed to the diverse postulated antidepressant mechanisms, which include both NMDA-dependent and independent mechanisms [8].”
BackgroundMatthews, K. A., Xu, W., Gaglioti, A. H., Holt, J. B., Croft, J. B., Mack, D., & McGuire, L. C. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.06.3063 · Cited by 1,124 · cited 1×
“8 million Americans were suffering from AD, and this number is projected to triple by 2060 [13].”
BackgroundCurrent and Future Treatments in Alzheimer Disease: An Update
Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966 · cited 15×
“However, the drug pimavanserin is a serotonin receptor antagonist that may soon receive approval by the FDA to treat AD-related psychosis [22].”
BackgroundInfluentialRaina, P., Santaguida, P., Ismaila, A., Patterson, C., Cowan, D., Levine, M., Booker, L., & Oremus, M. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-5-200803040-00009 · Cited by 771 · cited 2×
“Memantine can be used for moderate to severe AD in combination with acetylcholinesterase inhibitors, or on its own [24].”
BackgroundOverview of depression and psychosis in Alzheimer's disease
(1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.5.577 · Cited by 682 · cited 7×
“Imaging testing could help establish a diagnosis, which includes MRI, FDG-PET and SPECT, and the amyloid PET scan.”
BackgroundMethodInfluential
Research works printed but not linked: 6
- Chand, S.P., and Arif, H. (2022, February 07). Depression, StatPearls, Available online: http://www.ncbi.nlm.nih.gov/books/NBK430847/.
- (2022, February 07). Ketamine: A Neglected Therapy for Alzheimer Disease, Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667975/.
- Kuns, B., Rosani, A., and Varghese, D. (2022, February 07). Memantine, StatPearls, Available online: http://www.ncbi.nlm.nih.gov/books/NBK500025/.
- (2022, February 07). Memantine in Moderate-to-Severe Alzheimer’s Disease—PubMed, Available online: https://pubmed.ncbi.nlm.nih.gov/12672860/.
- (2022, February 07). Neuroinflammation and Microglial Activation in Alzheimer’s Disease: Where Do We Go from Here?—PubMed, Available online: https://pubmed.ncbi.nlm.nih.gov/33318676/.
- (2022, February 07). The Anti-Inflammatory Effects of Ketamine: State of the Art—PubMed, Available online: https://pubmed.ncbi.nlm.nih.gov/21612145/.
Cited by
(R)-ketamine as prophylactic and therapeutic drug for neurological disorders: Beyond depression
Wang, X., Yang, J., & Hashimoto, K. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104762 · Cited by 62
Pardossi, S., Fagiolini, A., & Cuomo, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313098 · Cited by 51
“In fact, recent clinical findings suggest that ketamine may provide neuroprotection and alleviate neuropsychiatric symptoms associated with Alzheimer’s disease, due to its ability to act as an NMDA receptor antagonist and modulate brain inflammation and glutamate-related neurotoxicity [93].”
Elsaeidy, A. S., Ahmad, A. H. M., Kohaf, N. A., Aboutaleb, A. M., Kumar, D., Elsaeidy, K. S., Mohamed, O. S., Kaye, A. D., & Shehata, I. M. (2024) · Current Pain and Headache Reports · doi:10.1007/s11916-023-01208-0 · Cited by 42
Self-citationThe neural basis of neuropsychiatric symptoms in Alzheimer’s disease
Zhang, N. K., Zhang, S. K., Zhang, L. I., Tao, H. W., & Zhang, G. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1487875 · Cited by 44
Sonic hedgehog signalling pathway contributes in age-related disorders and Alzheimer’s disease
Parashar, A., jha, D., Mehta, V., Chauhan, B., Ghosh, P., Deb, P. K., Jaiswal, M., & Prajapati, S. K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102271 · Cited by 28
Metadata
- Authors
- Mohammad Shehata, I., Masood, W., Nemr, N., Anderson, A., Bhusal, K., Edinoff, A. N., Cornett, E. M., Kaye, A. M., & Kaye, A. D.
- Affiliations
- Anesthesia Department, Faculty of Medicine, Ain Shams University, Cairo 11517, Egypt
- Dow University of Health Sciences (PK)
- Ain Shams University (EG)
- Louisiana State University Health Sciences Center Shreveport (US)
- University of the Pacific (US)
- Corresponding author
- Edinoff, Amber N.
- Venue
- Neurology International
- Publisher
- MDPI AG
- Published
- 2022-03-22
- Volume
- 14
- Issue
- 2
- Pages
- 310-321
- ISSN
- 2035-8377 (ISSN-L)
- PMC
- PMC9036213
- OpenAlex
- W4224839098
- Cited by
- 41
- References
- 47
- Citations by year
- 2026: 4 · 2025: 17 · 2024: 11 · 2023: 6 · 2022: 2
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Neurology International (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Scholarly Commons (University of the Pacific) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- ketamine, esketamine, Alzheimer's disease, depression, NMDA receptor antagonists, treatment-resistant depression, antidepressant efficacy, neuroprotection, glutamate receptors, neuropsychiatric symptoms, anti-inflammatory activity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Possible Application of Ketamine in the Treatment of Depression in Alzheimer’s Disease. https://app.cochat.ai/papers/10.3390/neurolint14020025
- The paper
- Mohammad Shehata, I., Masood, W., Nemr, N., Anderson, A., Bhusal, K., Edinoff, A. N., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2022). The Possible Application of Ketamine in the Treatment of Depression in Alzheimer’s Disease. Neurology International. https://doi.org/10.3390/neurolint14020025
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.